Pregabalin at 450 mg/day significantly reduced the average severity of pain in the primary analysis compared with placebo ( -0.93 on a 0-10 scale ) ( P < / = 0.001 ) , and significantly more patients in this group had > / = 50 % improvement in pain at the end point ( 29 % , versus 13 % in the placebo group ; P = 0.003 ) .
